Trials / Recruiting
RecruitingNCT05910398
Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer
Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: a Prospective, Randomised, Controlled, Multicentre Clinical Trial
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 488 (estimated)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, randomised, controlled, multicentre study to compare the efficacy and safety between continuous or intermittent extension of adjuvant pyrotinib in invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pyrotinib | an irreversible anti-HER2 tyrosine kinase inhibitor |
Timeline
- Start date
- 2023-06-01
- Primary completion
- 2030-04-01
- Completion
- 2030-08-01
- First posted
- 2023-06-18
- Last updated
- 2025-11-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05910398. Inclusion in this directory is not an endorsement.